Market Chatter: Johnson & Johnson Units to Pay $65 Million to Settle Tracleer Antitrust Lawsuit

MT Newswires Live02:46

Johnson & Johnson (JNJ) units Actelion Pharmaceuticals and Janssen Research & Development have agreed to pay $65 million to settle a proposed antitrust class action alleging overcharging for the pulmonary artery hypertension drug Tracleer, Reuters reported Friday.

The Government Employees Health Association and other entities that paid or reimbursed payments made by their members for Tracleer alleged in the lawsuit that the companies delayed competition for a generic version of the drug, according to the report.

The preliminary settlement, which covers Tracleer purchases in 31 states, the District of Columbia and Puerto Rico from December 2015 to September 2024, was filed Wednesday in Maryland federal court and requires approval from a judge, Reuters said.

Johnson & Johnson did not immediately respond to MT Newswires' request for comment.

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

Price: 238.77, Change: -0.86, Percent Change: -0.36

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2617327266?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-07 02:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2617327266","market":"nz","top_or_hot":-1,"title":"Market Chatter: Johnson & Johnson Units to Pay $65 Million to Settle Tracleer Antitrust Lawsuit","media":"MT Newswires Live","content":"<html><body><p> Johnson &amp; Johnson (JNJ) units Actelion Pharmaceuticals and Janssen Research &amp; Development have agreed to pay $65 million to settle a proposed antitrust class action alleging overcharging for the pulmonary artery hypertension drug Tracleer, Reuters reported Friday.</p><p>The Government Employees Health Association and other entities that paid or reimbursed payments made by their members for Tracleer alleged in the lawsuit that the companies delayed competition for a generic version of the drug, according to the report.</p><p>The preliminary settlement, which covers Tracleer purchases in 31 states, the District of Columbia and Puerto Rico from December 2015 to September 2024, was filed Wednesday in Maryland federal court and requires approval from a judge, Reuters said.</p><p>Johnson &amp; Johnson did not immediately respond to MT Newswires' request for comment.</p><p>(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)</p><p>Price: 238.77, Change: -0.86, Percent Change: -0.36</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Market Chatter: Johnson & Johnson Units to Pay $65 Million to Settle Tracleer Antitrust Lawsuit</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMarket Chatter: Johnson & Johnson Units to Pay $65 Million to Settle Tracleer Antitrust Lawsuit\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-03-07 02:46</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Johnson &amp; Johnson (JNJ) units Actelion Pharmaceuticals and Janssen Research &amp; Development have agreed to pay $65 million to settle a proposed antitrust class action alleging overcharging for the pulmonary artery hypertension drug Tracleer, Reuters reported Friday.</p><p>The Government Employees Health Association and other entities that paid or reimbursed payments made by their members for Tracleer alleged in the lawsuit that the companies delayed competition for a generic version of the drug, according to the report.</p><p>The preliminary settlement, which covers Tracleer purchases in 31 states, the District of Columbia and Puerto Rico from December 2015 to September 2024, was filed Wednesday in Maryland federal court and requires approval from a judge, Reuters said.</p><p>Johnson &amp; Johnson did not immediately respond to MT Newswires' request for comment.</p><p>(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)</p><p>Price: 238.77, Change: -0.86, Percent Change: -0.36</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00B2B36J28.USD","symbol_name":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2617327266","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2617327266","pubTimestamp":1772822786,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Johnson & Johnson  units Actelion Pharmaceuticals and Janssen Research & Development have agreed to pay $65 million to settle a proposed antitrust class action alleging overcharging for the pulmonary artery hypertension drug Tracleer, Reuters reported Friday.The Government Employees Health Association and other entities that paid or reimbursed payments made by their members for Tracleer alleged in the lawsuit that the companies delayed competition for a generic version of the drug, according to the report.The preliminary settlement, which covers Tracleer purchases in 31 states, the District of Columbia and Puerto Rico from December 2015 to September 2024, was filed Wednesday in Maryland federal court and requires approval from a judge, Reuters said.Johnson & Johnson did not immediately respond to MT Newswires' request for comment.Price: 238.77, Change: -0.86, Percent Change: -0.36","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","LU1066051225.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AC\" (USD) ACC","LU2505996681.GBP":"WELLINGTON MULTI-ASSET HIGH INCOME \"AM4H\" (GBPHDG) INC","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","LU1674673691.USD":"HSBC GIF GLOBAL LOWER CARBON EQUITY \"AD\" (USD) INC","LU0889566641.SGD":"FTSF - Templeton Shariah Global Equity A Acc SGD","BK4585":"ETF&股票定投概念","LU0345770993.USD":"NINETY ONE GSF GLOBAL STRATEGIC EQUITY \"A\" (USD) INC","SG9999002232.USD":"Allianz Global High Payout USD","JNJ":"强生","LU1674673428.USD":"HSBC GIF GLOBAL LOWER CARBON EQUITY \"AC\" (USD) ACC","LU0985320562.USD":"NORDEA 1 GLOBAL STARS EQUITY \"BP\" (USD) ACC","IE00BVYPNV92.GBP":"GUINNESS GLOBAL EQUITY INCOME \"C\" (GBP) ACC","IE00BGHQF631.EUR":"GUINNESS GLOBAL EQUITY INCOME \"C\" (EUR) ACC","LU0234570918.USD":"高盛全球核心股票组合Acc Close","SG9999002224.SGD":"Allianz Global High Payout SGD","LU1506573853.SGD":"MANULIFE GF GLOBAL EQUITY \"AA\" (SGD) INC","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","IE00BDGV0183.EUR":"GUINNESS GLOBAL EQUITY INCOME \"C\" (EUR) INC","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","IE00B3T34201.USD":"BNY MELLON GLOBAL EQUITY INCOME \"B\" (USD) INC","LU2129689605.HKD":"FRANKLIN GLOBAL INCOME \"A\" (HKD) INC","LU1162221912.USD":"FRANKLIN INCOME \"A\" (USD) ACC","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","LU0882574055.USD":"富达全球健康医疗A ACC","LU2129689514.USD":"FRANKLIN GLOBAL INCOME \"A\" (USD) INC","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD","LU1929549753.HKD":"FRANKLIN INCOME \"A\" (HKD) INC","LU1221951046.USD":"NORDEA 1 STABLE RETURN \"HM\" (USDHDG) INC","IE000M9KFDE8.USD":"NEUBERGER BERMAN US LARGE CAP VALUE \"A\" (USD) ACC","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","LU0122379950.USD":"贝莱德世界健康科学A2","LU0203347892.USD":"SCHRODER ISF QEP GLOBAL ACTIVE VALLUE \"A\" (USD)  INC AV","LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","LU2430703095.HKD":"WELLINGTON MULTI-ASSET HIGH INCOME \"AM4\" (HKD) INC","LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","LU0345769631.USD":"NINETY ONE GSF GLOBAL EQUITY \"A\" (USD) INC","LU0058720904.USD":"联博国际健康护理基金A","LU0792757196.USD":"TEMPLETON SHARIAH GLOBAL EQUITY FUND \"A\" (USD) ACC","LU1894683264.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) ACC","LU0098860793.USD":"FRANKLIN INCOME \"A\" INC","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","SG9999001440.SGD":"United Global Dividend Equity Fund A SGD Dist","LU2430703251.USD":"WELLINGTON MULTI-ASSET HIGH INCOME \"AM4\" (USD) INC","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC"},"translate_title":"市场热议：强生子公司将支付6500万美元和解Tracleer反垄断诉讼","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"JNJ":1.5},"content_text":"Johnson & Johnson (JNJ) units Actelion Pharmaceuticals and Janssen Research & Development have agreed to pay $65 million to settle a proposed antitrust class action alleging overcharging for the pulmonary artery hypertension drug Tracleer, Reuters reported Friday.The Government Employees Health Association and other entities that paid or reimbursed payments made by their members for Tracleer alleged in the lawsuit that the companies delayed competition for a generic version of the drug, according to the report.The preliminary settlement, which covers Tracleer purchases in 31 states, the District of Columbia and Puerto Rico from December 2015 to September 2024, was filed Wednesday in Maryland federal court and requires approval from a judge, Reuters said.Johnson & Johnson did not immediately respond to MT Newswires' request for comment.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)Price: 238.77, Change: -0.86, Percent Change: -0.36","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2617327266","isCrawlerRequest":true}